Physiological Basis
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan present in the extracellular matrix of connective tissue throughout the human body. In its cross-linked injectable form — produced by linking HA polymer chains to increase viscosity, cohesivity, and resistance to enzymatic degradation — it has an established safety record spanning decades of use in facial soft tissue augmentation. Cross-linked HA fillers are hygroscopic: they attract and retain water molecules from surrounding tissue, maintaining volume and integrating gradually with the local extracellular matrix over weeks following injection.
When delivered into the sub-dartos plane of the penis — the anatomical layer between the dartos fascia superficially and Buck's fascia deep — cross-linked HA distributes circumferentially around the penile shaft, adding girth uniformly without penetrating the compartment containing the erectile bodies, dorsal neurovascular bundle, or urethra. The sub-dartos plane is the anatomically appropriate injection plane for penile girth augmentation: it is sufficiently superficial to remain outside the structures of erectile function, sufficiently deep to produce cosmetically smooth augmentation, and allows circumferential distribution that manual massage can render uniform. Because the HA is deposited entirely outside Buck's fascia, the procedure does not directly affect corpora cavernosa tumescence, arterial inflow, venous outflow, or penile nerve function when performed in the correct anatomical plane.
A critical pharmacological advantage of HA is its enzymatic reversibility. Hyaluronidase — a naturally occurring enzyme that cleaves hyaluronic acid polymer chains — can be injected into treated tissue to dissolve HA filler rapidly and reliably. This reversibility distinguishes HA augmentation from permanent or semi-permanent alternatives (silicone injection, fat transfer) and provides a meaningful safety margin in the event of a complication or patient dissatisfaction.
The Treatment Protocol
EMLA topical anaesthetic cream is applied to the penile shaft 45 to 60 minutes before the procedure and covered with an occlusive dressing to maximise dermal penetration. Immediately prior to injection, a penile dorsal nerve block is performed using 1–2% lidocaine delivered at the base of the penis bilaterally, anaesthetising the dorsal penile nerves and providing comfortable procedural conditions. The treating physician identifies one or a small number of entry points on the penile shaft. A blunt-tipped microcannula or fine needle is advanced into the sub-dartos plane, and pharmaceutical-grade cross-linked HA filler is distributed using retrograde linear threading and fanning injection techniques — depositing filler in multiple overlapping passes to ensure even three-dimensional distribution throughout the plane.
Following injection, the physician performs manual massage and moulding to ensure circumferential uniformity and eliminate any localised areas of excess volume. A light compressive dressing is applied for 24 to 48 hours post-procedure. Total filler volumes typically range from 10 to 30 mL depending on the patient's baseline anatomy and the desired degree of augmentation. Post-procedure swelling and minor ecchymosis are expected for 5 to 14 days, with the final result becoming assessable once oedema has resolved — typically at 2 to 4 weeks. A touch-up session at 6 to 12 months is available to address volume loss from initial HA resorption or to correct any minor asymmetry.
Who is a Candidate
Adult males seeking non-surgical circumferential girth augmentation are the primary candidacy group. HA injection is particularly suitable for patients who value reversibility — the ability to dissolve the filler with hyaluronidase if the result is unsatisfactory or a complication occurs distinguishes this approach from surgical fat transfer or permanent implants. Men who have had suboptimal outcomes from autologous fat transfer (irregularity, resorption asymmetry) may benefit from HA as a more predictable alternative. Patients wishing to evaluate the subjective experience of girth augmentation before committing to a permanent surgical approach can use HA as a reversible trial. Anticoagulation therapy requires physician-directed management of coagulation status prior to any injection procedure.
Absolute contraindications include active penile infection or inflammation, documented hypersensitivity to hyaluronic acid or lidocaine, and unrealistic expectations regarding the degree of augmentation achievable — HA injection adds circumferential girth but does not increase penile length. Patients on therapeutic anticoagulation require individual risk-benefit assessment and, in many cases, a hold period under physician supervision before elective injection. Any previous silicone injection into the penile shaft is a relative contraindication requiring careful pre-procedure assessment, as silicone disrupts tissue planes and complicates safe cannula navigation.
Expected Outcomes and Timeline
Augmentation is visible immediately following the procedure, though post-injection swelling obscures the true result for the first 1 to 2 weeks. A clinically meaningful circumferential girth addition of 1 to 3 cm at the mid-shaft is achievable with standard filler volumes (10–30 mL), though individual anatomy, tissue compliance, and filler volume selected all influence the final result. Results are highly technique-dependent: even distribution of filler in the sub-dartos plane requires a physician experienced in penile injection to avoid localised nodularity or asymmetric augmentation. Duration of results ranges from 12 to 24 months before gradual HA resorption reduces the augmentation — resorption is typically gradual and can be supplemented with touch-up treatment before full resolution. Dissolution with hyaluronidase remains effective and reliable throughout the duration of the filler's presence.
Safety Profile and Risks
Lumpiness or irregular contour is the most common adverse outcome and is almost exclusively technique-dependent — occurring when filler is not distributed evenly in the sub-dartos plane, when a superficial injection plane is inadvertently used, or when insufficient post-injection massage is performed. It is correctable with hyaluronidase dissolution and re-treatment by an experienced physician. Filler migration — displacement of HA from the injection site toward the prepuce or base of the shaft — can occur and is similarly addressed with hyaluronidase. Prolonged oedema beyond 2 weeks is uncommon. Infection requires prompt antibiotic management and, in severe cases, hyaluronidase dissolution.
Cost and Accessibility
Procedure cost varies with the volume of filler used. Pharmaceutical-grade cross-linked HA (CE-marked or FDA-cleared dermal filler products used off-label for penile augmentation) represents a significant portion of the procedure cost — clinical-grade HA products are substantially more expensive per mL than non-medical-grade alternatives. The physician's time for the consultation, nerve block, injection, and moulding technique, along with facility overhead, constitutes the remainder. Penile HA augmentation is a cash-pay procedure with no insurance coverage.
Selecting a Qualified Provider
Physicians performing penile hyaluronic acid enhancement should hold ABU board certification in urology and have completed specific formal training in penile injection anatomy and filler technique — not merely transferred skills from facial filler experience. The sub-dartos penile injection plane has distinct anatomical requirements that differ from facial augmentation planes. SMSNA membership and engagement with the sexual medicine literature reflect familiarity with the emerging evidence base and complication management standards for this procedure. Prospective patients should ask about the physician's specific training in penile injection, the brand and regulatory status of the HA filler to be used, and whether hyaluronidase is available on-site for immediate complication management.